Log In
Print
BCIQ
Print
Print this Print this
 

MM-302

  Manage Alerts
Collapse Summary General Information
Company Merrimack Pharmaceuticals Inc.
DescriptionPegylated liposomal doxorubicin formulation targeting HER2
Molecular Target Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase II
Standard IndicationBreast cancer
Indication DetailsTreat advanced HER2-positive breast cancer; Treat HER2-positive, locally advanced or metastatic breast cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today